An estimated 1,000,000 people in the U.S. have hypertrophic cardiomyopathy. Washington University interventional cardiologist Richard Bach, MD, FACC, and his team had exhausted non-invasive treatments for a patient suffering from HCM. Until, that is, Bach enrolled the man, who was in his 50s, in a clinical trial evaluating a drug called mavacamten.
New Drug, Positive Results for Hypertrophic Cardiomyopathy (Links to an external site)
